The Claim
In adults with obesity and moderate-to-severe knee osteoarthritis, once-weekly subcutaneous semaglutide at a dose of 2.4 mg administered over 68 weeks results in significantly greater mean percentage body weight reduction (13.7%) compared to placebo (3.2%), which may lead to improvement in obesity-related joint symptoms.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly shot called semaglutide helped people with obesity and bad knee arthritis lose way more weight—about 13.7% of their body weight—compared to a fake shot that only led to 3.2% loss, and that weight loss might help their joint pain feel better.
See the scientific wording
Once-weekly subcutaneous semaglutide at a dose of 2.4 mg for 68 weeks leads to significantly greater weight loss compared to placebo in adults with obesity and moderate-to-severe knee osteoarthritis, with a mean percentage body weight reduction of 13.7% versus 3.2%, which may improve obesity-related joint symptoms.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
The study gave semaglutide to people with obesity and knee arthritis and found they lost much more weight than those who got a placebo, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.